Introduction {#Sec1}
============

White adipose tissue (WAT) has crucial functions in maintaining whole body energy homeostasis, and its unique lipid storage capacity helps to prevent ectopic lipid deposition and lipotoxicity \[[@CR1], [@CR2]\]. At times of energy surplus, NEFAs are deposited as triacylglycerols (TGs) in adipocytes for storage within cellular lipid droplets. Conversely, when energy becomes scarce, TGs are hydrolysed in a tightly controlled process known as lipolysis \[[@CR2], [@CR3]\]. Disrupting the delicate balance between lipid storage and mobilisation results in dysfunctional WAT and abnormalities in systemic lipid partitioning, which form the basis of metabolic diseases, for example in obesity and lipodystrophy \[[@CR1], [@CR4]\]. Since the storage and release of lipids are critical determinants of WAT integrity and organismal energy homeostasis, these processes are under tight regulation by the central nervous system as well as by counter-regulatory hormones \[[@CR1], [@CR2]\]. While insulin promotes TG storage, catecholamines induce lipolysis through β-adrenergic activation of protein kinase A (PKA). PKA promotes lipolysis by phosphorylating hormone-sensitive lipase (HSL; encoded by *Lipe*) and indirect activation of adipose triacylglycerol lipase (ATGL; encoded by *Pnpla2*) by phosphorylating the lipid droplet coating protein perilipin 1. Subsequently, perilipin 1 releases comparative gene identification-58 (CGI-58) from its interaction at the lipid droplet surface, thereby enabling CGI-58 to act as ATGL coactivator \[[@CR5]\]. Although the hormonal control of lipase activation is well understood, less is known about how lipid mobilisation is transcriptionally controlled in adipocytes.

Transcription factors and associated co-regulators operate in concert to regulate metabolic pathways by modulating target gene expression via integrating endocrine, paracrine and metabolic signals \[[@CR6]--[@CR8]\]. Components of the Janus kinase (JAK)--signal transducer and activator of transcription (STAT) pathway contribute to adipocyte physiology and the pathophysiology of dysfunctional adipose tissue \[[@CR9]--[@CR14]\]. STAT5A and STAT5B (collectively referred to as STAT5) are components of the JAK--STAT pathway that are involved in adipocyte development \[[@CR13], [@CR15], [@CR16]\]. However, the functions regulated by STAT5 in mature adipocytes and their consequences in vivo are largely unknown. Adipose STAT5 is prominently activated by growth hormone (GH) via JAK2 \[[@CR13]\]. GH induces lipolysis in WAT \[[@CR17], [@CR18]\]; circulating levels of GH negatively correlate with WAT mass \[[@CR19], [@CR20]\] and adipocyte-specific deletion of *Jak2* consistently blocks GH-induced lipolysis \[[@CR14], [@CR21]\]. GH deficiency or defective GH receptors (GHRs) result in increased adiposity; in line with these findings, GH levels are frequently reduced in common obesity \[[@CR18], [@CR19]\]. Although these observations implicate STAT5 in WAT lipid metabolism, the functional importance of adipocyte STAT5 has not been genetically defined, nor have its downstream molecular mechanisms been determined.

Here, we investigated the role of STAT5 in WAT lipid homeostasis using an adipocyte-specific gene knockout in mice. To prevent interference with adipogenesis due to STAT5 deficiency, we used the *Adipoq*--Cre transgenic mice to restrict *Stat5* deletion to mature adipocytes \[[@CR22]\].

Methods {#Sec2}
=======

Animal experiments {#FPar1}
------------------

Adipocyte-specific STAT5-deficient mice (*Stat5* ^*Adipoq*^) were generated by crossing *Adipoq*--Cre \[[@CR8]\] to *Stat5a/b* floxed mice \[[@CR23]\]. Mice were housed under standardised conditions (12 h dark/12 h light cycle). Unless stated otherwise, experiments used 2-month-old male *Stat5* ^*Adipoq*^ mice or *Adipoq*--Cre negative littermates (controls; C57BL/6 background) fed a standard diet ad libitum. Animal experimentation was approved by the institutional ethics and animal welfare committee and the national authority according to Section 26 of the Animal Experiments Act (Tierversuchsgesetz 2012). Body composition was determined using an EchoMRI-100H system (EchoMRI, Houston, TX, USA). For insulin tolerance tests (ITTs), 0.75 U/kg insulin was i.p. injected into 4 h fasted mice. For OGTTs and pyruvate tolerance tests (PTTs), 1 g/kg glucose was administered via oral gavage or 2 g/kg pyruvate was i.p. injected into overnight fasted mice. The HOMA-IR was calculated from insulin and glucose levels in 4 h fasted mice: (fasting glucose \[mmol/l\] × fasting insulin \[pmol/l\]) ÷ 135. Acute β-adrenergic stimulation was performed by i.p. injection of 1 mg/kg CL-316243. Blood was collected 20 min after injection.

Histological analysis {#FPar2}
---------------------

Formaldehyde-fixed tissues were dehydrated, paraffin-embedded, sliced, stained with haematoxylin and eosin using standard procedures and analysed by light microscopy. Adipocyte sizes were quantified from at least four different fields per mouse using ImageJ (Bethesda, MD, USA). STAT5 staining was performed as previously described \[[@CR24]\].

Metabolite measurements {#FPar3}
-----------------------

Blood glucose and β-ketones were measured directly from tail vein blood using a glucometer (Abbott, Chicago, IL, USA). All other metabolites were measured with commercial colorimetric assays or ELISA (listed in [electronic supplementary material](#Sec5){ref-type="sec"} \[ESM\] Methods, Metabolite measurements).

Quantitative real-time PCR and western blotting {#FPar4}
-----------------------------------------------

For RNA extraction, the RNeasy Lipid Tissue Mini Kit (Qiagen, Venlo, Netherlands) was used for tissue samples and Trizol (Thermo Fisher Scientific, Waltham, MA, USA) for 3T3-L1 adipocyte samples. RNA was reverse transcribed and cDNA was subjected to quantitative real-time PCR (qPCR) using the CFX96 Real-Time System (BioRad, Hercules, CA, USA). Samples were run in duplicate. Primers are listed in ESM Table [1](#MOESM1){ref-type="media"}. Protein extraction and western blots (40 μg protein samples) were performed as previously described \[[@CR25]\]; antibody suppliers are listed in ESM Methods, Western blotting.

Ex vivo measurement of lipolysis {#FPar5}
--------------------------------

Lipolysis of WAT explants was measured as previously described \[[@CR26]\]. Explants were stimulated with 10 μmol/l isoprenaline or 500 ng/ml GH.

Cell culture and adipocyte isolation {#FPar6}
------------------------------------

Differentiated 3T3-L1 adipocytes were incubated with GH (500 ng/ml) and/or an equimolar concentration of insulin for 6 h. For luciferase reporter assays, transfections were performed with Lipofectamine 2000 (Thermo Fisher Scientific). Cells were lysed in passive lysis buffer and luciferase activities were measured using the Dual Luciferase Reporter Assay system (Promega, Fitchburg, WI, USA). The generation of reporter constructs is described in ESM Methods, Cell culture and adipocyte isolation. Adipocyte isolation was performed using standard procedures and is described in ESM Methods, Cell culture and adipocyte isolation.

Electrophoretic mobility shift assay and chromatin immunoprecipitation {#FPar7}
----------------------------------------------------------------------

Electrophoretic mobility shift assay \[[@CR25]\] and chromatin immunoprecipitation (ChIP) \[[@CR27]\] were performed as previously described. Detailed description is available in ESM Methods, Electrophoretic mobility shift assay and chromatin immunoprecipitation.

Statistical analysis {#FPar8}
--------------------

Results are presented as means ± SEM. Two-tailed Student's *t* tests and Wilcoxon rank-sum tests were used for comparing two groups and one-way ANOVA followed by Tukey's honestly significant difference, Dunn's multiple comparison or Bonferroni post hoc tests were used for comparing multiple groups. Tolerance tests were analysed with repeated measures two-way ANOVA followed by Bonferroni post hoc testing. Levels of statistical significance were set at \**p \<* 0.05, \*\**p \<* 0.01 and \*\*\**p \<* 0.001.

Results {#Sec3}
=======

Adipose STAT5 deficiency results in increased adiposity and reduced basal lipolysis {#FPar9}
-----------------------------------------------------------------------------------

Immunostaining showed STAT5 levels were significantly reduced in epididymal WAT (EWAT), subcutaneous WAT (ScWAT) and interscapular brown adipose tissue (BAT) of *Stat5* ^*Adipoq*^ mice, but were unaffected in the liver (ESM Fig. [1a](#MOESM1){ref-type="media"}). Western blot analysis confirmed that STAT5 was barely detectable in extracts of isolated white adipocytes and in BAT from *Stat5* ^*Adipoq*^ mice (Fig. [1a](#Fig1){ref-type="fig"}, ESM Fig. [1b](#MOESM1){ref-type="media"}). Eight-week-old male *Stat5* ^*Adipoq*^ mice had a greater total fat mass compared with littermate controls, while their lean mass and body weight were unaltered (Fig. [1b](#Fig1){ref-type="fig"}). EWAT, BAT, liver and gastrocnemius muscle weight was unchanged, but ScWAT weight was significantly increased (Fig. [1c](#Fig1){ref-type="fig"}, ESM Fig. [1c, d](#MOESM1){ref-type="media"}). *Stat5* ^*Adipoq*^ EWAT contained a higher proportion of large adipocytes (Fig. [1d](#Fig1){ref-type="fig"}). Conversely, subcutaneous adipocytes from knockout and control animals were similar in size, suggesting that the higher amount of ScWAT in *Stat5* ^*Adipoq*^ mice was due to increased adipocyte numbers. However, levels of the adipocyte differentiation marker proteins peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding proteins (C/EBP) α and δ in ScWAT were similar between genotypes (ESM Fig. [1e, f](#MOESM1){ref-type="media"}). C/EBPα content was increased only in EWAT. In contrast, mRNA levels for genes involved in fatty acid (FA) and TG synthesis, such as acetyl-CoA carboxylase (*Acaca*), fatty acid synthase (*Fasn*), PEPCK (*Pck1*) and diacylglycerol O-acyltransferase 2 (*Dgat2*), were decreased in both WAT compartments of *Stat5* ^*Adipoq*^ mice (Fig. [1e, f](#Fig1){ref-type="fig"}). An increase in neither total STAT3 levels nor phosphorylation status was detectable in *Stat5* ^*Adipoq*^ WAT, suggesting that a compensatory increase in STAT3 function does not occur in response to adipose STAT5-deficiency (ESM Fig. [1g](#MOESM1){ref-type="media"}). In addition, neither typical inflammatory mRNA marker levels in WAT nor plasma IL-6 and TNF-α levels were significantly different between genotypes (ESM Fig. [1h--k](#MOESM1){ref-type="media"}). Furthermore, macrophage-related transcripts were not differentially expressed in WAT. Although not significant, plasma leptin concentration was slightly increased, while adiponectin concentration was mildly decreased (ESM Fig. [1l, m](#MOESM1){ref-type="media"}). GH levels were similar between genotypes, as were plasma TG and blood β--ketone levels (ESM Fig. [1n--p](#MOESM1){ref-type="media"}). Notably, circulating NEFA and glycerol levels were markedly decreased, indicating reduced lipid mobilisation in *Stat5* ^*Adipoq*^ mice (Fig. [1g, h](#Fig1){ref-type="fig"}). Consistent with this, basal lipolysis (determined by NEFA and glycerol release from WAT explants of fed mice) was reduced upon STAT5 deficiency (Fig. [1i, j](#Fig1){ref-type="fig"}). Therefore, our results show that adipose STAT5 deficiency increases body fat mass, which coincides with a decrease in basal lipolysis.Fig. 1Adipocyte STAT5 deficiency promotes increased adiposity and decreased basal lipolysis. (**a**) Western blotting of isolated epididymal and subcutaneous (sc) white adipocyte protein lysates. (**b**) Body composition analysis (*n* ≥ 8). (**c**) Fat depot weight in relation to body weight (BW) (*n* ≥ 7). (**d**) Haematoxylin and eosin staining of WAT. Scale bar, 100 μm. Cell size was quantified using ImageJ (*n* ≥ 6). (**e**, **f**) Relative mRNA content for genes involved in lipid synthesis in (**e**) EWAT and (**f**) ScWAT. C~t~ values were normalised to *Gapdh* mRNA levels (*n* ≥ 5). (**g**) Plasma NEFA and (**h**) glycerol levels (*n* ≥ 6). (**i**) Basal lipolysis as indicated by NEFA and (**j**) glycerol release from WAT explants (*n* ≥ 6). \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. White bars, control; black bars, *Stat5* ^*Adipoq*^. Rel, relative

Improved variables of glucose metabolism in *Stat5*^*Adipoq*^ mice {#FPar10}
------------------------------------------------------------------

Given the interdependence of lipid and glucose metabolism, we next addressed the impact of adipose STAT5 deficiency on systemic glucose homeostasis. Four h fasted *Stat5* ^*Adipoq*^ and control mice had similar blood glucose levels, despite *Stat5* ^*Adipoq*^ mice having lower insulin levels, consistent with their lower HOMA-IR (Fig. [2a--c](#Fig2){ref-type="fig"}). Liver glycogen stores were reduced in *Stat5* ^*Adipoq*^ mice (Fig. [2d](#Fig2){ref-type="fig"}), suggesting that either glycogenolysis is increased or glycogen synthesis is reduced to maintain normoglycaemia. OGTTs revealed no difference in glucose clearance between *Stat5* ^*Adipoq*^ and control littermates (Fig. [2e](#Fig2){ref-type="fig"}). However, post-hypoglycaemic recovery in *Stat5* ^*Adipoq*^ mice during ITTs was delayed: glucose levels reached only 60% of starting values at the end of the experiment (Fig. [2f](#Fig2){ref-type="fig"}). As this observation suggests a reduction in counter-regulatory mechanisms such as hepatic glucose production, we performed PTTs to measure hepatic gluconeogenesis indirectly. In agreement with ITT findings, glucose production from pyruvate was reduced in *Stat5* ^*Adipoq*^ mice (Fig. [2g](#Fig2){ref-type="fig"}). Interestingly, activating Akt S473 phosphorylation upon insulin injection was similar in liver and WAT lysates from both genotypes (Fig. [2h](#Fig2){ref-type="fig"}).Fig. 2Variables of glucose metabolism are improved in *Stat5* ^*Adipoq*^ mice. (**a**) Blood glucose and (**b**) plasma insulin levels in 4 h fasted mice (*n* ≥ 6). (**c**) HOMA-IR was calculated from glucose and insulin levels of 4 h fasted mice (*n* ≥ 6). (**d**) Liver glycogen content in fed mice (*n* ≥ 6). (**e**) OGTT: 1 g/kg glucose was administered via oral gavage in 16 h fasted mice. (**f**) ITT: 0.75 U/kg insulin was i.p. injected into 4 h fasted mice. (**g**) PTT: 2 g/kg pyruvate was i.p. injected into 16 h fasted mice (*n* ≥ 7). (**h**) Western blotting of insulin-stimulated (0.75 U/kg body weight) Akt phosphorylation in liver and EWAT lysates. \**p* \< 0.05; \*\**p* \< 0.01. White bars and circles, control; black bars and squares, *Stat5* ^*Adipoq*^

As ageing is linked to deterioration in glucose metabolism, we investigated whether STAT5 deficiency also has beneficial metabolic effects at older ages. Similar to young mice, total fat mass and ScWAT mass were increased in 52-week-old *Stat5* ^*Adipoq*^ male mice (Fig. [3a](#Fig3){ref-type="fig"}; ESM Fig. [2a](#MOESM1){ref-type="media"}). Plasma NEFA and glycerol levels remained lower and blood β-ketones were reduced in aged *Stat5* ^*Adipoq*^ mice (Fig. [3b--d](#Fig3){ref-type="fig"}). Although fasting blood glucose levels were decreased in aged *Stat5* ^*Adipoq*^ mice, glucose tolerance was similar between genotypes (Fig. [3e, f](#Fig3){ref-type="fig"}). However, the increased insulin sensitivity was preserved in aged *Stat5* ^*Adipoq*^ animals, as was their reduced capacity to produce glucose from pyruvate (Fig. [3g, h](#Fig3){ref-type="fig"}).Fig. 3Improved insulin sensitivity in aged *Stat5* ^*Adipoq*^ mice. (**a**) Body composition analysis (*n* = 5), (**b**) plasma NEFA and (**c**) glycerol (*n* ≥ 7), (**d**) blood β-ketone and (**e**) glucose levels in 4 h fasted 52-week-old mice (*n* = 10). (**f**) OGTT: 1 g/kg glucose was administered via oral gavage in 16 h fasted mice. (**g**) ITT: 0.75 U/kg insulin was i.p. injected into 4 h fasted mice. (**h**) PTT: 2 g/kg pyruvate was i.p. injected into 16 h fasted mice (*n* ≥ 4). All tolerance tests were performed in 52-week-old mice. \**p* \< 0.05, \*\**p* \< 0.01. White bars and circles, control; black bars and squares, *Stat5* ^*Adipoq*^

Together, these data show that adipose STAT5 deficiency results in decreased insulin resistance scores and reduced gluconeogenic capacity.

Acute β-adrenergic induction of lipolysis is not impaired in *Stat5*^*Adipoq*^ mice {#FPar11}
-----------------------------------------------------------------------------------

Our results demonstrated that basal lipolytic capacity was reduced upon STAT5 deficiency. We next determined the lipolytic response to acute β-adrenergic stimulation by treating WAT explants with isoprenaline. NEFA and glycerol levels in media from isoprenaline-stimulated *Stat5* ^*Adipoq*^ WAT explants were reduced (Fig. [4a, b](#Fig4){ref-type="fig"}, ESM Fig. [3a, b](#MOESM1){ref-type="media"}), while the fold induction of isoprenaline-stimulated lipolysis over baseline was increased (Fig. [4c, d](#Fig4){ref-type="fig"}). Lipolytic products were also reduced upon GH stimulation of *Stat5* ^*Adipoq*^ WAT explants. However, GH-mediated induction of lipolysis was only significantly decreased in STAT5-deficient ScWAT explants (Fig. [4a--d](#Fig4){ref-type="fig"}). To determine the responses to acute β-adrenergic stimulation in vivo, we treated mice with CL-316243 (a β~3~-adrenergic agonist). Although the fold induction of lipolysis was similar among genotypes, *Stat5* ^*Adipoq*^ mice displayed a ∼25% decrease in plasma glycerol and NEFA levels upon CL-316243 treatment (Fig. [4e, f](#Fig4){ref-type="fig"}, ESM Fig. [3c](#MOESM1){ref-type="media"}). These findings indicate that β-adrenergic responsiveness in *Stat5* ^*Adipoq*^ mice is intact, although the resulting induction rate is not sufficient to restore circulating lipolytic products to control levels.Fig. 4Acute β-adrenergic induction of lipolysis is not impaired in *Stat5* ^*Adipoq*^ mice. (**a**, **b**) Basal and isoprenaline (Iso)- and GH-stimulated lipolysis represented by NEFA and glycerol release from (**a**) EWAT and (**b**) ScWAT explants (*n* ≥ 5). (**c**, **d**) Fold change in glycerol levels over basal after stimulation of (**c**) EWAT and (**d**) ScWAT explants. (**e**) CL-316243-stimulated glycerol levels in plasma (*n* ≥ 5). (**f**) Fold change in glycerol levels over basal after CL-316243 treatment (*n* ≥ 5). \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. White bars, control; black bars, *Stat5* ^*Adipoq*^. Stim, stimulated

Adipocyte-specific STAT5 deficiency impairs fasting-induced lipid mobilisation {#FPar12}
------------------------------------------------------------------------------

Given the inability of *Stat5* ^*Adipoq*^ mice to compensate for defective basal release of lipolytic products upon acute β-adrenergic stimulation, we determined their ability to respond to a situation that requires lipolysis by subjecting them to a 48 h fast. There was no difference in overall body weight loss between fasted *Stat5* ^*Adipoq*^ and control mice (ESM Fig. [4a](#MOESM1){ref-type="media"}). However, *Stat5* ^*Adipoq*^ mice lost less fat mass and more lean mass during this intervention (Fig. [5a, b](#Fig5){ref-type="fig"}, ESM Fig. [4b, c](#MOESM1){ref-type="media"}). Accordingly, loss of WAT mass was decreased and loss of liver mass was increased in fasted *Stat5* ^*Adipoq*^ mice, while no changes were observed in gastrocnemius muscle and BAT weight (Fig. [5c--e](#Fig5){ref-type="fig"}, ESM Fig. [4d--h](#MOESM1){ref-type="media"}). Their inefficient lipid mobilisation was further supported by WAT histological analysis (Fig. [5f](#Fig5){ref-type="fig"}): control adipocytes displayed drastic cell shrinkage upon fasting compared with the fed state, whereas STAT5-deficient adipocytes were almost unaffected by fasting. Plasma NEFA and glycerol concentrations remained lower in 48 h fasted *Stat5* ^*Adipoq*^ mice compared with controls and fasting-associated lipid accumulation was reduced within *Stat5* ^*Adipoq*^ livers (Fig. [5g--i](#Fig5){ref-type="fig"}, ESM Fig [4i](#MOESM1){ref-type="media"}). Plasma TG levels were elevated and GH levels showed a slight but non-significant increase in fasted *Stat5* ^*Adipoq*^ mice (Fig. [5j, k](#Fig5){ref-type="fig"}). Despite the reduction in lipolytic products as substrates for energy production, fasting blood glucose and β-ketone levels were similar among genotypes (Fig. [5l, m](#Fig5){ref-type="fig"}), suggesting that catabolism of non-adipose tissue in *Stat5* ^*Adipoq*^ mice (i.e. the liver) might compensate for missing substrates that are usually provided by WAT lipid mobilisation. Taken together, our results suggest that adipose STAT5 is required not only for basal lipolysis but also for efficient lipid mobilisation under 48 h fasting conditions.Fig. 5Impaired lipid mobilisation during fasting in *Stat5* ^*Adipoq*^ mice. (**a**, **b**) Loss of (**a**) total fat and (**b**) lean mass over fed state (baseline) after fasting (*n* ≥ 6). (**c**--**e**) Loss of WAT and liver mass over baseline after fasting (*n* ≥ 6). (**f**) Haematoxylin and eosin staining of WAT at baseline and after fasting (staining of WAT at baseline is depicted again here \[as well as in Fig. [1d](#Fig1){ref-type="fig"}\] for the purpose of comparison). Scale bar, 100 μm. (**g**) Plasma NEFA and (**h**) glycerol levels in 48 h fasted mice (*n* ≥ 6). (**i**) Liver triacylglycerol content in 48 h fasted mice. (**j**--**m**) Blood and plasma metabolite and cytokine levels in 48 h fasted mice. (*n* ≥ 6). \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. White bars, control; black bars, *Stat5* ^*Adipoq*^

Impaired lipolysis in *Stat5*^*Adipoq*^ mice is linked to reduced ATGL and CGI-58 levels {#FPar13}
----------------------------------------------------------------------------------------

To gain insight into the molecular changes underlying the lipolytic defect of fed and 48 h fasted *Stat5* ^*Adipoq*^ mice, we measured the mRNA levels for key lipolytic genes in EWAT. No changes were detected in fed or fasting *Lipe* (encoding HSL), *Mgll* (encoding monoacylglycerol lipase) and *Plin1* (encoding perilipin 1) mRNA levels in STAT5-deficient compared with control EWAT. In contrast, mRNA levels of *Pnpla2* (encoding ATGL) and its coactivator *Abhd5* (encoding CGI-58) were diminished in the fed state (Fig. [6a--c](#Fig6){ref-type="fig"}, ESM Fig. [5a, b](#MOESM1){ref-type="media"}). Although fasting significantly increased *Pnpla2* and *Abhd5* expression in both genotypes, levels in *Stat5* ^*Adipoq*^ mice remained significantly lower, indicating that the baseline defect cannot be efficiently compensated for by fasting. Notably, ATGL and CGI-58 protein levels were decreased in EWAT from fed and fasted *Stat5* ^*Adipoq*^ mice, whereas phosphorylation status and total levels of HSL as well as PKA activity were similar between the genotypes (Fig. [6d, e](#Fig6){ref-type="fig"}). Interestingly, perilipin 1 levels in the fed state were reduced, which might be a compensatory mechanism to facilitate access of lipases to the lipid droplet TG moiety. These results suggest that β-adrenergic signalling is not impaired in *Stat5* ^*Adipoq*^ mice and indicate that inefficient lipid mobilisation is probably due to reduced levels of ATGL and CGI-58.Fig. 6Impaired lipolysis in *Stat5* ^*Adipoq*^ mice is associated with decreased ATGL and CGI-58 levels. (**a**--**c**) EWAT mRNA levels for lipolytic genes in fed and 48 h fasted mice. C~t~ values were normalised to *Gapdh* mRNA levels (*n* ≥ 5). (**d**, **e**) Western blot of EWAT lysates shows lipolytic protein activation status and/or total levels (*n* ≥ 3). \**p* \< 0.05, \*\**p* \< 0.01; \*\*\**p* \< 0.001; ^†^ *p* = 0.053. White bars, control; black bars, *Stat5* ^*Adipoq*^. Rel, relative

STAT5 controls *Pnpla2* expression in WAT {#FPar14}
-----------------------------------------

We next performed a series of experiments to investigate the mechanisms by which STAT5 controls ATGL and CGI-58 levels. Consistent with our in vivo findings, *Pnpla2* and *Abhd5* mRNA levels in STAT5-deficient explants were reduced, while *Lipe* expression was unchanged (Fig. [7a](#Fig7){ref-type="fig"}, ESM Fig. [6a, b](#MOESM1){ref-type="media"}). After GH stimulation for 2 h, *Pnpla2* mRNA was upregulated in control explants, suggesting transcriptional activation of the *Pnpla2* gene. Consistent with this observation, GH stimulation of 3T3-L1 adipocytes significantly upregulated *Pnpla2* and restored insulin-mediated downregulation of *Pnpla2* to basal levels (\[[@CR28]\], Fig. [7b](#Fig7){ref-type="fig"}, ESM Fig. [6c](#MOESM1){ref-type="media"}). Moreover, this treatment was sufficient to stimulate *Abhd5* upregulation in 3T3-L1 adipocytes (Fig. [7b](#Fig7){ref-type="fig"}). Consequently, we investigated whether STAT5 transcriptionally regulates *Pnpla2* and *Abhd5*. We identified a functional *Stat5* response element (RE) within the *Pnpla2* promoter region (−1428 to −1419 bp) and the *Abhd5* promoter region (−1389 to −1380 bp) by electrophoretic mobility shift assay (Fig. [7c, d](#Fig7){ref-type="fig"}). To confirm that STAT5 associates with the identified chromatin regions, we performed ChIP in EWAT extracts. Enriched binding of GH-activated STAT5 was observed on the *Pnpla2* promoter and, to a lesser extent, on the *Abhd5* promoter (Fig. [7e](#Fig7){ref-type="fig"}). To validate the functionality of the identified REs, we performed reporter assays in NIH3T3 cells in which luciferase gene expression was regulated by either a 146 bp fragment of the *Pnpla2* promoter (*Pnpla2*-luc) or a 138 bp fragment of the *Abhd5* promoter (*Abhd5*-luc) containing the respective *Stat5* RE. For *Abhd5*-luc, reporter gene activity was not induced above empty vector levels (ESM Fig. [6d](#MOESM1){ref-type="media"}); however, *Pnpla2*-luc had significantly elevated luciferase activity, which was further increased by GH stimulation (Fig. [7f](#Fig7){ref-type="fig"}). Mutation of the *Stat5* RE within the *Pnpla2* promoter fragment (*Pnpla2*-mutS5RE-luc) decreased luciferase gene expression to empty vector levels. In line with this, *Pnpla2*-luc reporter activity was abolished in *Stat5*-null mouse embryonic fibroblasts and restored by *Stat5a* co-expression (ESM Fig. [6e](#MOESM1){ref-type="media"}). These data provide mechanistic evidence that STAT5 is a transcriptional regulator of the *Pnpla2* gene in WAT.Fig. 7STAT5 controls *Pnpla2* expression in WAT. (**a**) *Pnpla2* mRNA levels in EWAT explants. C~t~ values were normalised to *Gapdh* mRNA levels (*n* ≥ 6). White bars, control; Black bars, *Stat5* ^*Adipoq*^. (**b**) *Pnpla2* and *Abhd5* mRNA levels in 3T3-L1 adipocytes. C~t~ values were normalised to *36B4* mRNA levels (*n* = 8). White bars, PBS; black bars, GH. (**c**) Putative *Stat5* REs in the promoter regions of *Pnpla2* and *Abhd5*. Numbers indicate the distance from translation start site. (**d**) Electrophoretic mobility shift assay. *Csn2* (encoding β-Casein) RE served as a positive control. (**e**) ChIP in EWAT. Binding of STAT5 to the *Igf1* promoter served as a positive control. The horizontal line indicates the threshold for non-specific binding (*n* ≥ 5). White bars, IgG; black bars, STAT5. (**f**) Luciferase reporter assay in NIH3T3 cells transfected with the respective reporter construct (*n* ≥ 5). \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. White bars, empty vector; black bars, *Pnpla2*-Luc; grey bars, *Pnpla2*-mutS5Re-luc. Luc, luciferase; Rel, relative; Ren, *Renilla*

Discussion {#Sec4}
==========

We report a previously unanticipated requirement for STAT5 in maintaining lipid homeostasis in WAT. Basal lipolysis and fasting-induced lipid mobilisation were diminished by STAT5 deficiency, which was associated with decreased ATGL and CGI-58 levels. We provide further evidence that *Pnpla2* is transcriptionally regulated by STAT5 in WAT. Despite increased adiposity, a lack of STAT5 in adipocytes promoted improved insulin sensitivity and reduced gluconeogenic capacity in mice.

STAT5 deficiency differentially affected the two main WAT compartments: ScWAT mass was substantially increased despite unaltered adipocyte size, while EWAT mass was unchanged although characterised by adipocyte hypertrophy. Preferential enlargement of ScWAT has been noted upon adipocyte-specific deletion of *Jak2* using *Adipoq*--Cre \[[@CR21]\] and in adipose *Ghr* deleted male mice using aP2-Cre \[[@CR29]\], which may reflect different responses to GH in the respective WAT compartments \[[@CR30]\]. Interestingly, adipose *Jak2* deletion using aP2-Cre resulted in significant enlargement of all fat depots, although ScWAT showed the greatest increase \[[@CR14]\]. This difference may be attributable to the age, genetic background or Cre-promoter usage. A characteristic feature of both STAT5-deficient WAT compartments was a reduced capacity for basal lipolysis accompanied by decreased mRNA levels for genes involved in FA and TG synthesis (i.e. *Acaca*, *Fasn*, *Pck1* and *Dgat2*). Interestingly, chronic stimulation of lipolysis was shown to coincide with an upregulation of genes involved in FA and TG synthesis \[[@CR31]\], while blockage of lipolysis in chow- and HFD-fed mice resulted in downregulation of these genes \[[@CR32], [@CR33]\]. These studies established possible interdependence between lipid mobilisation and synthesis in adipocytes and may explain the reduced expression of lipid storage related genes in STAT5-deficient WAT.

Our results indicate that β-adrenergic responsiveness in *Stat5* ^*Adipoq*^ mice is intact, although the lipolysis induction rate was not sufficient to compensate for the defective basal release of lipolytic products upon acute β-adrenergic stimulation. Similarly, the basal defect was not efficiently compensated for by fasting and thus contributed to aberrant fasting responses. On the molecular level, neither the levels nor activation status of HSL or PKA activity were altered in WAT *Stat5* ^*Adipoq*^ mice. This finding supports the observation that impaired lipid mobilisation in *Stat5* ^*Adipoq*^ mice is not due to defective β-adrenergic signalling and argues against STAT5-dependent regulation of HSL levels in WAT. Adipose STAT5 deficiency resulted in reduced ATGL and CGI-58 levels, thereby impacting the lipolytic machinery at other crucial nodes. In contrast to post-translational regulation of ATGL activity by CGI-58 and G0S2 \[[@CR3], [@CR34]\], little is known about the direct transcriptional regulators of *Pnpla2*: feeding and insulin both repress *Pnpla2* expression via the FoxO1 transcription factor, whereas fasting and PPARγ agonists elevate *Pnpla2* mRNA levels \[[@CR2], [@CR3], [@CR28], [@CR35]\]. Our study extends this knowledge by providing several lines of evidence supporting *Pnpla2* regulation by adipose STAT5: (1) *Pnpla2* expression is significantly increased by GH only in control WAT explants; (2) STAT5 is enriched at the *Pnpla2* promoter in WAT; and (3) a *Pnpla2* promoter fragment containing the *Stat5* RE activates a reporter gene. The presence of defects in basal lipolysis in *Stat5* ^*Adipoq*^ mice raises the possibility that STAT5 is implicated in balancing lipid metabolism in WAT. This effect may involve pulsatile GH secretion and/or its counter-regulatory effects on insulin function \[[@CR18]\] to maintain baseline levels of ATGL and lipid turnover. In support of this notion, GH treatment of 3T3-L1 adipocytes restored insulin-mediated downregulation of *Pnpla2* to basal levels. At this point, we cannot exclude the possibility that additional mechanisms contribute, directly or indirectly, to impaired lipolysis in *Stat5* ^*Adipoq*^ mice. Given that ATGL activity requires CGI-58 \[[@CR3]\], it is conceivable that defective lipolysis results from the simultaneous decrease in the levels of both proteins. However, as we could not show that the *Abhd5* promoter fragment has transactivation potential in reporter assays, further studies are needed to precisely define the underlying molecular mechanism.

STAT5 deficiency in WAT improved variables of glucose metabolism. Adipose tissue has a central role in glucose homeostasis and the lipolytic capacity of WAT negatively correlates with insulin sensitivity \[[@CR1], [@CR2], [@CR32], [@CR33]\]. Consistent with this, *Stat5* ^*Adipoq*^ mice displayed reduced insulin resistance scores and improved insulin sensitivity in ITTs. These results contrast with those of adipocyte *Jak2* deletion, which does not alter glucose metabolism in young mice but leads to insulin resistance accompanied by increased circulating NEFA in aged animals \[[@CR14]\]. Despite the ability of *Stat5* ^*Adipoq*^ mice to maintain euglycaemia during fasting periods, their gluconeogenic capacity in tolerance tests was reduced (i.e. post-hypoglycaemic recovery, gluconeogenesis from pyruvate). It is worth considering that glucose production can be limited by WAT-derived substrate fluxes as glycerol is a direct gluconeogenic substrate, while NEFA oxidation indirectly activates gluconeogenesis via allosteric effectors \[[@CR36]--[@CR38]\]. Hence, diminished NEFA and glycerol availability as well as the depletion of liver glycogen may contribute to the reduced glucose production of *Stat5* ^*Adipoq*^ mice.

Collectively, our results identify STAT5 as a pivotal regulator of basal lipolysis that is needed for WAT to respond efficiently to altered energy demands. Moreover, our data indicate that glucose metabolism can be improved by interfering with adipose STAT5. Thus, our study not only extends the current understanding of WAT physiology but also provides a rationale for future studies into the potential of STAT5 manipulation to improve outcomes in metabolic diseases.
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ATGL

:   Adipose triglyceride lipase

BAT

:   Brown adipose tissue

CGI-58

:   Comparative gene identification-58

ChIP

:   Chromatin immunoprecipitation

EWAT

:   Epididymal white adipose tissue

FA

:   Fatty acid

GH

:   Growth hormone

GHR

:   Growth hormone receptor

HSL

:   Hormone-sensitive lipase

ITT

:   Insulin tolerance test

JAK

:   Janus kinase

PKA

:   Protein kinase A

PTT

:   Pyruvate tolerance test

RE

:   Response element

ScWAT

:   Subcutaneous white adipose tissue

STAT

:   Signal transducer and activator of transcription

TG

:   Triacylglycerols

WAT

:   White adipose tissue
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